Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

Even as Novo Nordisk and Eli Lilly found themselves unable to fully serve demand, they still brought in billions of dollars ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk (NVO) teased some new details about a potential Ozempic successor during a call with investors Tuesday. The ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

"Don't risk your health trying to get healthy," she said. Novo Nordisk, the maker of Ozempic, Rybelsus and Wegovy, said in a statement to CBS News: "It's important that patients are aware that Novo ...

Since Eli Lilly's Mounjaro and Novo Nordisk's Wegovy and Ozempic fell into shortage in late 2022, compounding pharmacies have been manufacturing their respective generics, tirzepatide and semaglutide.